Case Report: KLHL11 encephalitis in a female patient with dual primary malignancies of breast and lung cancer: response to FcRn inhibitor therapy [PDF]
Frontiers in ImmunologyKelch-like protein 11 (KLHL11) encephalitis is a rare clinical condition characterized by autoimmune-mediated encephalitis associated with the presence of KLHL11 antibodies, which commonly presents with ataxia, diplopia, vertigo, hearing loss, and ...
Yapeng Li +8 more
doaj +4 more sources
Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders [PDF]
Frontiers in Immunology, 2022 Serum albumin (SA), the most abundant soluble protein in the body, maintains plasma oncotic pressure and regulates the distribution of vascular fluid and has a range of other important functions.
E. Sally Ward +15 more
doaj +2 more sources
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers [PDF]
Clinical and Translational Science, 2021 Blockade of the binding between neonatal Fc receptor and IgG‐Fc reduces circulating IgG, and thus emerges as a potential therapy for IgG‐mediated autoimmune conditions.
Desmond Y. H. Yap +7 more
doaj +2 more sources
Structure of the human astrovirus capsid spike in complex with the neonatal Fc receptor [PDF]
Nature CommunicationsHuman astroviruses (HAstVs) are a leading cause of viral gastroenteritis in children worldwide. Recently the neonatal Fc receptor (FcRn) was identified as a receptor for HAstV, however the molecular basis for the FcRn-HAstV interaction remained unclear ...
Adam Lentz +5 more
doaj +2 more sources
Frontiers in Immunology, 2022 BackgroundImmunoglobulin G (IgG) levels are maintained by the IgG-recycling neonatal Fc-receptor (FcRn). Pemphigus vulgaris and pemphigus foliaceus are debilitating autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal ...
Maud Maho-Vaillant +13 more
doaj +3 more sources
Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network [PDF]
Frontiers in ImmunologyObjectiveTo integrate pharmacovigilance and network pharmacology methods for a comprehensive analysis of the potential adverse reactions of complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan) and neonatal Fc receptor (FcRn) inhibitors ...
Luqiong Wang +5 more
doaj +2 more sources
FcRn Blockade as a Targeted Therapeutic Strategy in Antibody-Mediated Autoimmune Diseases: A Focus on Warm Autoimmune Hemolytic Anemia [PDF]
AntibodiesAntibody-mediated autoimmune diseases are common, can involve any organ system, and pose a large burden for patients and healthcare systems. Most antibody-mediated diseases are mediated by IgG antibodies.
Michael Sandhu, Irina Murakhovskaya
doaj +2 more sources
Tumor intrinsic properties dictate Fc receptor expression and cancer cachexia associated increase in checkpoint inhibitor clearance [PDF]
Frontiers in ImmunologyPurposePatients with cancer cachexia display a general resistance to immune checkpoint inhibitor (ICI) therapy, and baseline ICI catabolic clearance is a predictive indicator for overall survival, independent of dose and drug exposure.
Bryan C. Remaily +35 more
doaj +2 more sources
Efgartigimod for treating Guillain-Barré syndrome with poor response to intravenous immunoglobulin: a case report [PDF]
BMC NeurologyBackground Guillain-Barré syndrome (GBS) is a peripheral neuropathy mediated by immunoglobulin G (IgG) autoantibodies, which can cause acute flaccid paralysis. Miller-Fisher syndrome (MFS) is a variant of GBS, and in some cases, MFS may overlap with GBS (
Bai Qi Hu +4 more
doaj +2 more sources
Pharmacological ResearchHigh baseline clearance of immune checkpoint inhibitors (ICIs), independent of dose or systemic exposure, is associated with cachexia and poor outcomes in cancer patients.
Trang T. Vu +20 more
doaj +3 more sources